J&J/Basilea's Ceftobiprole Faces Another Setback
This article was originally published in Pharmaceutical Approvals Monthly
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits
You may also be interested in...
Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.
Safety signal from trials appears in FDA’s briefing materials, but not in list of questions for the Anti-Infective Drugs Advisory Committee.
“Approvable” word from FDA represents a victory in tough antibiotic field.